

# LONG QT SYNDROME

## Cardiff Joint Obstetric and Anaesthetic Antenatal Clinic

An abnormality of cardiac repolarisation which may be either inherited or acquired

Predisposes to the development of malignant ventricular arrhythmias triggering syncope, seizures and sudden cardiac death in an otherwise healthy individual

**Effect on pregnancy:** Increased chance of arrhythmia, highest risk postpartum.

Aim to continue beta blockers throughout pregnancy and particularly in the postpartum period.

<b>Incidence</b>	1 in approximately 8 000
<b>Presentation:</b>	Family history, or may be index case Arrhythmia- palpitations, atypical syncope especially during exercise Characteristic ECG abnormality with cardiac symptoms
<b>Precipitated by:</b>	Certain drugs, electrolyte abnormalities, hypothermia, exercise, emotion
<b>Diagnosis:</b>	Genetic testing if a carrier of a recognised mutation (30% of people with long QT do not have a recognised mutation) ECG – (resting ECG may be normal). Duration of Q-T interval corrected for heart rate (QTc) is best prognostic indicator Longer QTc times are associated with higher risk.
<b>ECG:</b>	Prolonged QTc >470ms in adult females (Bazzett's formula)
<b>Anatomy:</b>	Structurally normal heart
<b>Treatment:</b>	<b>Main stay of treatment is beta blocker therapy</b> which reduces the chances of sudden cardiac death. High risk individuals may be fitted with an implantable cardiac defibrillator (ICD)

### Inherited

Genetic abnormality affecting specific of K<sup>+</sup> Na<sup>+</sup> or Ca<sup>2+</sup> cardiac channels all affecting cardiac repolarisation

Most types autosomal dominant

12 different genotypes described; types 1,2 and 3 being the commonest.

Type	Genotype	Channelopathy	Incidence	Highest Risk
1	KCNQ1	K <sup>+</sup>	45%	Adrenergic stress, exercise
2	KCNH2	K <sup>+</sup>	40%	Adrenergic stress, increased risk post-partum
3	SCN5A	Na <sup>2+</sup>	5%	More common during rest/sleep
4 - 12			rare	

### Acquired

Often manifest in those with an underlying genetic predisposition.

Iatrogenic- QT prolonging medication

Metabolic eg severe anorexia nervosa

- Consider referral to Clinical Genetics for counselling and genetic testing
- Beta blockers (e.g. nadolol) are extremely protective in LQT1 patients and moderately protective in LQT2 and LQT3. Awareness of LQTS genotype allows selective use of Beta blockers. Beta blocker medication throughout pregnancy is associated with fetal growth restriction so offer fetal surveillance by serial growth scans (alternatively consider post-partum treatment).
- High risk individuals may be fitted with an implantable cardiac defibrillator (ICD) - arrange an ICD check & download
- **Avoid QT prolonging medication—please refer to full list at back of high risk folder at reception on delivery suite or see [www.crediblemeds.org](http://www.crediblemeds.org)**
- Risk of congenital LQTS with fetal heart block. Monitor fetal heart rate by auscultation or ultrasound every 4 weeks from 20 weeks gestation. Refer to fetal echo if persistent fetal bradycardia <110bpm.

## Peri-partum Care

### Continue beta blockers peripartum

Perform baseline ECG on admission and repeat if concerning symptoms of palpitations/ syncope  
Check U&E's- Maintain K<sup>+</sup> >4.5, correct hypomagnesaemia and hypocalcaemia  
Minimise sympathetic stress, consider early effective epidural & good postop pain control

**Ensure defibrillator is readily available** if ICD not in situ

**If ICD is fitted do not inactivate for labour.** Avoid unipolar diathermy in theatre.

*If unipolar diathermy must be used inactivate the ICD by securing a clinical magnet over the device (kept in cardiac arrest trolley on DS, theatre end). Fit defib pads while ICD inactivated.*

Avoid hypothermia- measure temp and institute active warming if indicated

**Avoid QT prolonging medication- for up to date information see [www.crediblemeds.org](http://www.crediblemeds.org)**

## Drugs specific to delivery

This list is not exhaustive. Please check other medications at [www.crediblemeds.org](http://www.crediblemeds.org)

<b>Antiemetics</b>	Dexamethasone, cyclizine safe. <b>Avoid</b> Ondansetron, metoclopramide
<b>Analgesia</b>	Morphine, paracetamol, NSAIDs – safe. Tramadol—avoid as possible risk
<b>Antibiotics</b>	Augmentin and cefuroxime safe. <b>Check other antibiotics.</b>
<b>Tocolytics</b>	Avoid terbutaline, GTN is safe alternative
<b>Regional anaesthesia</b>	Safe
<b>Vasopressors</b>	Phenylephrine/metaraminol first choice, avoid ephedrine if possible
<b>GA induction</b>	Opiates safe- give short acting to obtund the pressor response to intubation. Thiopentone- safe, Propofol- probably safe Rocuronium and sugammadex- safe. <b>Avoid</b> Suxamethonium and Neostigmine/glycopyrrolate Sevoflurane controversial- change to isoflurane if time allows, <b>if not proceed</b>
<b>GA maintenance</b>	Avoid hypercapnoea. N2O- safe

## Malignant Arrhythmias

- **Manage according to advanced life support guidelines and defibrillate if indicated**
- Use Magnesium sulphate to prevent recurrence of arrhythmia. Use 2g over 3-4 minutes
- Loading dose, may be repeated after 15 minutes. Loading dose may be used prophylactically in high risk situations.
- Supplement K<sup>+</sup> to >4.5mM/L
- Consider trans-venous pacing to increase heart rate in recurrent Torsades
- Avoid QT prolonging antiarrhythmics- amiodarone and flecainide contraindicated

### References

- Anaesthesia for patients with hereditary arrhythmias; part 2: congenital long QT syndrome and arrhythmogenic right ventricular cardiomyopathy, *BJA Education*, 18(8): 246-253. D. Levy, C. Bingham, D. Tomlinson (2018).
- Anaesthesia in long QT syndrome. Continuing education in Anaesthesia Critical care and pain, John D Hunter 2008
- Anaesthesia for Patients with Congenital Long QT Syndrome *Anesthesiology* 2005; 102:204–10, Susan J. Kies, M.D., Christina M. Pabelick, M.D.,† Heather A. Hurley, Pharm.D.,‡ Roger D. White, M.D.,§Michael J. Ackerman, M.D., Ph.D
- Uptodate accessed 31/08/2016
- Crediblemeds.org.uk accessed 17/11/20
- Perioperative management of hereditary arrhythmogenic syndromes *Br J. Anaesth.* (2012) 108 (5): 730-744. doi: 10.1093/bja/aes105 C. Staikou\*, K. Chondrogiannis and A. Mani